ReviewCurrent treatment options in oncology2018
Follicular Lymphoma: Past, Present, and Future.
Review in Current treatment options in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- [Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Two B or not two B; the question of bendamustine dosing in low grade lymphoma.Pathology oncology research : POR · 2025Article
- [Prognostic value and imaging features of (18)F-FDG PET-CT in follicular lymphoma with different histopathology grade].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma.Investigational new drugs · 2023Article
- Machine learning models-based on integration of next-generation sequencing testing and tumor cell sizes improve subtype classification of mature B-cell neoplasms.Frontiers in oncology · 2023Article
- Article
- Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure.American journal of cancer research · 2022Article
- Article
- Article
- The clinicopathological features of parotid lymphoma.International journal of clinical and experimental pathology · 2020Article
- Lymphoma of the female genital tract: a clinicopatholngical analysis of 25 cases.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementEven in the modern era, follicular lymphoma (FL) remains largely an incurable but treatable disease with both standard and novel treatment modalities. Despite the abundance of efficacious treatment modalities currently available, there is no universally agreed upon standard approach to treatment for patients with FL, particularly in the relapsed/refractory (R/R) setting. There is an increasing need for better tools to risk-stratify patients and to identify those likely to experience relapse early. Additionally, the use of gene expression profiling and next-generation sequencing techniques in recent years has led to a wealth of knowledge regarding the molecular drivers of lymphomagenesis; however, much of this knowledge is not currently applicable on a day to day basis in the clinic setting. Further studies are needed to determine a validated, clinically relevant predictive model that incorporates patient factors and molecular factors that will guide clinicians on the most effective treatment strategy. With many questions left unanswered, it is our opinion that the treatment of FL and sequencing of therapy in the R/R setting should be a personalized approach that balances patient-specific factors such as preferences and comorbidities with treatment-related factors such as known response rates and toxicity profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.